Benzamide Anti-inflammatory Composition Reducing Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory therapies face challenges in effectively inhibiting inflammatory mediators and cytokines without causing toxicity, particularly in addressing the production of NO and PGE2, expression of iNOS and COX-2, and activity of transcription factors like NF-κB and AP-1.
Innovation Solution
A composition containing 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide, its isomers, pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, which inhibits the production of NO and PGE2, expression of iNOS and COX-2, and activity of NF-κB and AP-1, offering superior anti-inflammatory effects while being non-toxic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory therapies are used to inhibit inflammatory mediators and cytokines, then anti-inflammatory effect is improved, but toxicity increases
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of benzamide compounds to achieve superior anti-inflammatory activity with reduced toxicity. Specifically, the compound 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide exhibits potent inhibition of inflammatory mediators (NO, PGE2) and cytokines (IL-1β, TNF-α) while demonstrating lower toxicity compared to conventional therapies. This structural parameter modification allows the compound to selectively target inflammatory pathways without the harmful side effects of traditional anti-inflammatory drugs
2Reliability
If strong anti-inflammatory agents are used to inhibit production of NO and PGE2, then anti-inflammatory activity is improved, but harmful side effects increase
Solution Approach 1:
The patent converts the potential harm of strong anti-inflammatory agents into benefit by designing a compound that selectively inhibits harmful inflammatory mediators (NO, PGE2) and proinflammatory cytokines (IL-1β, TNF-α) while avoiding the harmful side effects associated with conventional strong anti-inflammatory drugs. The compound achieves this by targeting specific enzymatic pathways (iNOS, COX-2) and transcription factors (NF-κB, AP-1) involved in inflammation, thereby converting the general suppression of inflammation into targeted therapy that eliminates harmful effects
Data Source
AI summary
5-Adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide disclosed in the present disclosure lacks toxicity and can exhibit superior anti-inflammatory effect. It exhibits superior anti-inflammatory effect, for example, by inhibiting the production of one or more of NO and PGE2, by inhibiting the activity of one or more of the transcription factors NF-κB and AP-1 or by inhibiting proinflammatory cytokines such as IL-1β.